CandlesenseCandlesense
LLY•benzinga•

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

Summary

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 7, 2025 by benzinga

← Back to LLY News
    Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook | LLY Stock News | Candlesense